APA (7th ed.) Citation

Banerjee, S., Vergotte, I., Colombo, N., Barve, M., Grisham, R., Mehr, K., . . . Birrer, M. (2019). 1060TiP - Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer. Annals of oncology, 30, v431-v432. https://doi.org/10.1093/annonc/mdz250.068

Chicago Style (17th ed.) Citation

Banerjee, S., et al. "1060TiP - Randomized, Phase Ib/II Study of M6620 + Avelumab + Carboplatin Vs Standard Care (sc) in Patients (pts) with Platinum-sensitive Poly (ADP-ribose) Polymerase Inhibitor-(PARPi)-resistant Ovarian Cancer." Annals of Oncology 30 (2019): v431-v432. https://doi.org/10.1093/annonc/mdz250.068.

MLA (9th ed.) Citation

Banerjee, S., et al. "1060TiP - Randomized, Phase Ib/II Study of M6620 + Avelumab + Carboplatin Vs Standard Care (sc) in Patients (pts) with Platinum-sensitive Poly (ADP-ribose) Polymerase Inhibitor-(PARPi)-resistant Ovarian Cancer." Annals of Oncology, vol. 30, 2019, pp. v431-v432, https://doi.org/10.1093/annonc/mdz250.068.